Enoxaparin Dosing for Peripheral Artery Disease (PAD)

Standard Dosing Regimens

• For general prophylaxis in PAD patients, enoxaparin 40 mg subcutaneously once daily is typically used 1
• For therapeutic anticoagulation in PAD patients, enoxaparin 1 mg/kg subcutaneously every 12 hours is the standard dose 2

Dosage Adjustments

• In patients with renal impairment (creatinine clearance <30 mL/min), the dose should be reduced to 1 mg/kg subcutaneously once daily 2
• For elderly patients ≥75 years, dose reduction may be necessary to 0.75 mg/kg subcutaneously every 12 hours 3
• Obese patients may require higher doses; weight-based dosing of 0.5 mg/kg subcutaneously every 12 hours may be more appropriate than fixed dosing 4

Clinical Considerations for PAD Patients

• Enoxaparin has better bioavailability, longer half-life, more predictable anticoagulation effect, less bleeding risk, and lower risk of heparin-induced thrombocytopenia compared to unfractionated heparin 4
• For patients undergoing percutaneous interventions for PAD, intravenous enoxaparin may be considered as an alternative to unfractionated heparin to reduce ischemic events 5, 6

Cautions and Contraindications

• Avoid switching between enoxaparin and unfractionated heparin due to increased bleeding risk 3
• Fondaparinux should not be used to support percutaneous interventions because of the risk of catheter thrombosis 5, 6
• For patients with high bleeding risk but requiring anticoagulation, bivalirudin may be considered as an alternative 2

Duration of Therapy

• For long-term management, the duration should be determined based on clinical indication and patient risk factors 1